Glaukos Corporation (GKOS)
| Market Cap | 14.54B +173.3% |
| Revenue (ttm) | 690.33M +46.9% |
| Net Income | -169.80M |
| EPS | -2.91 |
| Shares Out | 59.17M |
| PE Ratio | n/a |
| Forward PE | 189.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 546,460 |
| Open | 246.20 |
| Previous Close | 246.03 |
| Day's Range | 242.34 - 249.07 |
| 52-Week Range | 87.32 - 255.19 |
| Beta | 0.68 |
| Analysts | Strong Buy |
| Price Target | 242.46 (-1.33%) |
| Earnings Date | Oct 28, 2026 |
About GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and ... [Read more]
Financial Performance
In 2025, Glaukos's revenue was $507.44 million, an increase of 32.33% compared to the previous year's $383.48 million. Losses were -$187.69 million, 28.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for GKOS stock is "Strong Buy." The 12-month stock price target is $242.46, which is a decrease of -1.33% from the latest price.
News
Glaukos Transcript: Stifel 2026 Healthcare Conference 2026
Epioxa payer access has exceeded expectations, with 2027 growth dependent on patient access, awareness and payer execution. iDose retains long-term support, while 2027 spending priorities include launch expansion and pipeline investment.
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos Slides: Investor presentation
Glaukos has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, Oct. 30, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on Wednesday, N...
Glaukos to replace Okta in S&P 400 at open on 11/4
17:18 EDT Glaukos (GKOS) to replace Okta (OKTA) in S&P 400 at open on 11/4
McGrath RentCorp to replace Glaukos in S&P 600 at open on 11/4
17:19 EDT McGrath RentCorp (MGRC) to replace Glaukos (GKOS) in S&P 600 at open on 11/4
Glaukos price target raised to $248 from $195 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Glaukos (GKOS) to $248 from $195 and keeps a Buy rating on the shares. The company reported a Q3…
Glaukos price target raised to $240 from $200 at JPMorgan
JPMorgan raised the firm’s price target on Glaukos (GKOS) to $240 from $200 and keeps an Overweight rating on the shares.
Glaukos price target raised to $251 from $201 at Needham
Needham raised the firm’s price target on Glaukos (GKOS) to $251 from $201 and keeps a Buy rating on the shares. The company’s Q3 revenue beat consensus estimates driven by…
Glaukos price target raised to $234 from $205 at BTIG
BTIG analyst Ryan Zimmerman raised the firm’s price target on Glaukos (GKOS) to $234 from $205 and keeps a Buy rating on the shares. The company’s Q3 results were exceptional,…
Glaukos price target raised to $225 from $185 at Mizuho
Mizuho raised the firm’s price target on Glaukos (GKOS) to $225 from $185 and keeps an Outperform rating on the shares.
Glaukos price target raised to $225 from $190 at Stifel
Stifel analyst Thomas Stephan raised the firm’s price target on Glaukos (GKOS) to $225 from $190 and keeps a Buy rating on the shares.
Glaukos price target raised to $247 from $225 at Citi
Citi raised the firm’s price target on Glaukos (GKOS) to $247 from $225 and keeps a Buy rating on the shares.
Glaukos price target raised to $240 from $195 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Glaukos (GKOS) to $240 from $195 and keeps an Overweight rating on the shares. The firm notes Glaukos posted…
Glaukos reports Q3 EPS 47c, consensus (9c)
Reports Q3 revenue $,211.0M consensus $168.1M. “Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positi...
Glaukos sees FY26 revenue $775M-$785M, consensus $691.7M
16:31 EDT Glaukos (GKOS) sees FY26 revenue $775M-$785M, consensus $691.7M
Glaukos sees FY27 revenue at $1.0B, consensus $852.5M
16:31 EDT Glaukos (GKOS) sees FY27 revenue at $1.0B, consensus $852.5M
Glaukos up 14% after Q3 earnings beat, above-consensus guidance
16:32 EDT Glaukos (GKOS) up 14% after Q3 earnings beat, above-consensus guidance
Glaukos Earnings Call Transcript: Q3 2026
Q3 sales rose 58% to a record $211M, led by Epioxa and iDose. FY26 sales guidance increased to $775M-$785M, with preliminary FY27 revenue guidance of $1B despite potential iDose LCD scenarios.
Glaukos Earnings release: Q3 2026
Glaukos released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
Glaukos Quarterly report: Q3 2026
Glaukos has published its Q3 2026 quarterly earnings report on October 28, 2026.
Glaukos Announces Third Quarter 2026 Financial Results
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos price target raised to $190 from $185 at Mizuho
Mizuho raised the firm’s price target on Glaukos (GKOS) to $190 from $185 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices and…